ACKNOWLEDGING LIMITS: STATISTICS AND THE CHILD'S QUALITY OF LIFE IN SPINAL MUSCULAR ATROPHY

Franca Benini, Eleonora Salamon, Antuan Divisic, Irene Maghini, Caterina Agosto

Journal of Paediatrics and Child Health · 2020 · 10 citations · 1 references

DOIFull text

Open access

Concepts

Abstract

Dear Editor, Paediatricians are increasingly confronted with complex challenges such as the diagnosis of incurable illness and the limitations posed by medicine itself. Even the definition of incurable illness can frequently be problematic; as time passes the prognosis can change, not only because of the child's evolving maturity and the unpredictable trajectory of the illness but also due to therapeutic innovations. But the distinction between incurability and potential curability may become fuzzy, with inevitable consequences to the child's existence and quality of life. The problem is relevant when dealing with rare diseases where the severity of the illness and the consequential risks to life justify a fervent quest for effective solutions. However, at the same time, it must be acknowledged how the burden of the proposed treatments can condition their effectiveness and negatively impact the child and family's quality of life. Spinal muscular atrophy can be considered a paradigm: the availability of a recently approved drug has radically changed the course of the illness by offering patients an enhanced duration and quality of life. However, if this ground-breaking treatment is initiated late in the course of the disease, it does not significantly improve their clinical situation. On the contrary, the anxiety and distress caused by the prospect of being subjected to a burdensome lifelong procedure (it is administered every 4 months via spinal canal injection), linked to the frustration, triggered by disappointing results or the lack of improvement, can significantly impact the child and family's quality of life. Furthermore, the cost of the drug and of the hospital admissions must also be added to the balance.1, 2 Therefore, when evaluating the introduction of new treatments, as opposed to applying standardised protocols, we should always aim to adopt a flexible approach that takes into consideration each individual patient's global needs. We currently care for with 49 children with spinal muscular atrophy, patients at various stages of the disease (in terms of clinical subtype and degree of disease progression). For nine patients, drug therapy was never begun or was suspended after a careful evaluation of the actual benefits and the burden of the treatment. Today, we are increasingly faced with cogent clinical and bioethical dilemmas that impose a profound reflection on the appropriateness of medical interventions that should respect the best interest and the quality of life of the child living with serious illness.3

References

1